Cargando…

P797: A PHASE 2, OPEN-LABEL STUDY EVALUATING THE SAFETY AND EFFICACY OF COMBINATION POZELIMAB AND CEMDISIRAN THERAPY IN PATIENTS WITH PAROXYSMAL NOCTURNAL HEMOGLOBINURIA WHO SWITCH FROM ECULIZUMAB

Detalles Bibliográficos
Autores principales:	Kelly, Richard, Houghton, Nicola, Munir, Talha, Muus, Petra, Youngs, Nora, Aurand, Lisa, Senk, Brian, Pavani, Rodrigo, Perlee, Lorah, Souttou, Amal, Griffin, Morag
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Lippincott Williams & Wilkins 2023
Materias:	Posters
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10430561/ http://dx.doi.org/10.1097/01.HS9.0000970092.68730.83

Ejemplares similares

P782: A PHASE 2, RANDOMIZED TRIAL EVALUATING THE SAFETY AND EFFICACY OF POZELIMAB AND CEMDISIRAN IN PATIENTS WITH PAROXYSMAL NOCTURNAL HEMOGLOBINURIA
por: Jang, Jun-Ho, et al.
Publicado: (2023)

PB2044: FINAL PATIENT-REPORTED OUTCOMES FROM A PHASE 2, RANDOMISED TRIAL EVALUATING THE SAFETY AND EFFICACY OF POZELIMAB AND CEMDISIRAN IN PATIENTS WITH PAROXYSMAL NOCTURNAL HAEMOGLOBINURIA
por: Hartford, Christopher, et al.
Publicado: (2023)

Results of a phase 1/2 study of cemdisiran in healthy subjects and patients with paroxysmal nocturnal hemoglobinuria
por: Gaya, Anna, et al.
Publicado: (2023)

P775: LONG-TERM EFFICACY AND SAFETY OF POZELIMAB MONOTHERAPY IN PATIENTS WITH PAROXYSMAL NOCTURNAL HEMOGLOBINURIA
por: Jang, Jun-Ho, et al.
Publicado: (2023)

The pathophysiology of paroxysmal nocturnal hemoglobinuria and treatment with eculizumab
por: Kelly, Richard, et al.
Publicado: (2009)

Pharmacokinetics and pharmacodynamics of pozelimab alone or in combination with cemdisiran in non-human primates
por: Devalaraja-Narashimha, Kishor, et al.
Publicado: (2022)

Eculizumab in the management of paroxysmal nocturnal hemoglobinuria: patient selection and special considerations
por: Al-Ani, Fatimah, et al.
Publicado: (2016)

Treatment of paroxysmal nocturnal hemoglobinuria in pregnancy with eculizumab: A case report
por: Fassett, Michael J., et al.
Publicado: (2021)

Pharmacokinetic and Pharmacodynamic Properties of Cemdisiran, an RNAi Therapeutic Targeting Complement Component 5, in Healthy Subjects and Patients with Paroxysmal Nocturnal Hemoglobinuria
por: Badri, Prajakta, et al.
Publicado: (2020)

Thrombotic complications without evidence of hemolysis in paroxysmal nocturnal hemoglobinuria: is eculizumab indicated?
por: Bellido, M., et al.
Publicado: (2012)

Eculizumab in paroxysmal nocturnal hemoglobinuria with Budd-Chiari syndrome progressing despite anticoagulation
por: Brodsky, Andrés, et al.
Publicado: (2012)

Low-dose prednisolone in patients with paroxysmal nocturnal hemoglobinuria and inadequate response to eculizumab
por: Moon, Ji Young, et al.
Publicado: (2017)

Severe Infection of Pseudomonas aeruginosa during Eculizumab Therapy for Paroxysmal Nocturnal Hemoglobinuria
por: Kawakami, Toru, et al.
Publicado: (2017)

Atypical presentation of paroxysmal nocturnal hemoglobinuria treated by eculizumab: A case report
por: Quinquenel, Anne, et al.
Publicado: (2017)

C3 inhibition with pegcetacoplan in subjects with paroxysmal nocturnal hemoglobinuria treated with eculizumab
por: de Castro, Carlos, et al.
Publicado: (2020)

Effect of Eculizumab on Iron Metabolism in Transfusion-independent Patients With Paroxysmal Nocturnal Hemoglobinuria
por: Schaap, Charlotte C.M., et al.
Publicado: (2023)

Cost-effectiveness of ravulizumab compared with eculizumab for the treatment of paroxysmal nocturnal hemoglobinuria in the Netherlands
por: Quist, S. W., et al.
Publicado: (2023)

Correction to: Pharmacokinetic and Pharmacodynamic Properties of Cemdisiran, an RNAi Therapeutic Targeting Complement Component 5, in Healthy Subjects and Patients with Paroxysmal Nocturnal Hemoglobinuria
por: Badri, Prajakta, et al.
Publicado: (2022)

The use of the complement inhibitor eculizumab (Soliris®) for treating Korean patients with paroxysmal nocturnal hemoglobinuria
por: Kim, Jin Seok, et al.
Publicado: (2010)

Successful use of eculizumab in an 86-year-old patient with paroxysmal nocturnal hemoglobinuria in Japan
por: Ooe, Yokiko, et al.
Publicado: (2014)

Atypical presentation of paroxysmal nocturnal hemoglobinuria treated by eculizumab: A case report: Erratum
Publicado: (2017)

Eculizumab-Related Abortion in a Woman with Paroxysmal Nocturnal Hemoglobinuria: A Case Report
por: Rodríguez-Ferreras, Adrián, et al.
Publicado: (2019)

Norm-based comparison of the quality-of-life impact of ravulizumab and eculizumab in paroxysmal nocturnal hemoglobinuria
por: Schwartz, Carolyn E., et al.
Publicado: (2021)

Phase 2 study of danicopan in patients with paroxysmal nocturnal hemoglobinuria with an inadequate response to eculizumab
por: Kulasekararaj, Austin G., et al.
Publicado: (2021)

Prolonged Remission of Cancer of Unknown Primary following Initiation of Eculizumab Therapy for Paroxysmal Nocturnal Hemoglobinuria
por: Lim, Ming Y., et al.
Publicado: (2019)

Successful treatment of noncirrhotic portal hypertension with eculizumab in paroxysmal nocturnal hemoglobinuria: A case report
por: Alexopoulou, Alexandra, et al.
Publicado: (2019)

Switching From High-Dose Eculizumab to Ravulizumab in Paroxysmal Nocturnal Hemoglobinuria: A Case Report
por: Füreder, Wolfgang, et al.
Publicado: (2020)

Improvement of Renal Function by Long-Term Sustained Eculizumab Treatment in a Patient with Paroxysmal Nocturnal Hemoglobinuria
por: Ninomiya, Haruhiko, et al.
Publicado: (2015)

Long Standing Eculizumab Treatment without Anticoagulant Therapy in High-Risk Thrombogenic Paroxysmal Nocturnal Hemoglobinuria
por: Al-Jafar, Hassan A., et al.
Publicado: (2015)

Preoperative administration of eculizumab to prevent surgery‐triggered hemolysis during cesarean section with paroxysmal nocturnal hemoglobinuria
por: Li, Dongping, et al.
Publicado: (2018)

Prospective and comparative study of paroxysmal nocturnal hemoglobinuria patients treated or not by eculizumab: Focus on platelet extracellular vesicles
por: Devalet, Bérangère, et al.
Publicado: (2019)

The first case of paroxysmal nocturnal hemoglobinuria and Budd-Chiari syndrome treated with complement inhibitor eculizumab in Korea
por: Kim, Hyerim, et al.
Publicado: (2017)

Real-World Eculizumab Dosing Patterns Among Patients with Paroxysmal Nocturnal Hemoglobinuria in a US Population
por: Cheng, Wendy Y, et al.
Publicado: (2022)

Necrotizing Fasciitis in Paroxysmal Nocturnal Hemoglobinuria
por: Patir, Pusem, et al.
Publicado: (2015)

Evolutionary dynamics of paroxysmal nocturnal hemoglobinuria
por: Mon Père, Nathaniel, et al.
Publicado: (2018)

Renal Manifestations in Paroxysmal Nocturnal Hemoglobinuria
por: Ram, R., et al.
Publicado: (2017)

Insights Into the Emergence of Paroxysmal Nocturnal Hemoglobinuria
por: Colden, Melissa A., et al.
Publicado: (2022)

Management of paroxysmal nocturnal hemoglobinuria (PNH)
por: Luzzatto, Lucio
Publicado: (2022)

Paroxysmal Nocturnal Hemoglobinuria: Biology and Treatment
por: Bravo-Perez, Carlos, et al.
Publicado: (2023)

Early Mortality in Paroxysmal Nocturnal Hemoglobinuria
por: Sørensen, Anne Lykke, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_fg3jkj020hjfcl8qaa1akievta